Loading patent…
AssigneeNational University Corporation Hokkaido University
InventorsKen Kadoya, Yuki Suzuki, Akihito Sotome, Katsumi Maenaka, Satoko Otsuguro
Estimating the term…
The present invention relates to an agent for protection of vascular endothelial cells, an agent for protection of blood brain spinal cord barrier, and an agent for protection of central nervous system, containing at least one compound selected from the group consisting of muvritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition for the treatment of diseases associated with blood brain spinal cord barrier disruption, containing at least one compound selected from the group consisting of muvritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof.
A method for treating a disease accompanied with a blood brain spinal cord barrier disorder, comprising administering an effective amount of a bismuth-containing compound or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the disease accompanied with a blood brain spinal cord barrier disorder is selected from the group consisting of brain injury, spinal cord injury, and compressive myelopathy, and wherein the bismuth-containing compound is selected from the group consisting of bismuth subnitrate, bismuth subcitrate, and bismuth tartrate.
A method for treating a disease, comprising administering an effective amount of a bismuth-containing compound or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the disease is selected from the group consisting of brain injury, spinal cord injury, and compressive myelopathy, wherein the bismuth-containing compound is selected from the group consisting of bismuth subnitrate, bismuth subcitrate, and bismuth tartrate.
Dependencies are inferred from the claim text.